In line with Asymchem’s continuous strategic layout and development, the organization has welcomed Dr. Cheng Yi Chen as a senior executive.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240626665787/en/

Asymchem is pleased to announce Dr. Cheng Yi Chen has joined Asymchem as Small-Molecule Sector CTO. (Photo: Business Wire)

Dr. Cheng Yi Chen officially joined Asymchem as CTO of the Small-Molecule Sector on June 18, 2024. He will report directly to Asymchem’s CEO, Dr. Hao Hong. In this position, Dr. Cheng Yi Chen will provide technical support to the group’s chemical small molecule sales in the European and United States markets. His main duties include active participation in technical communications for key mid-to-late-stage clinical projects in Europe and United States and facilitating collaborations with crucial new clients by capitalizing on the overall technical capabilities of the group’s chemical small-molecule sector. He will also offer guidance to the China Core Team on project-related technical matters with European and United States clientele and provide advisory input for communication. Additionally, he will provide technical expertise suggestions for the Boston site in the United States, as well as supervising technical operations at small-molecule laboratories and pilot production sites across Europe.

Dr. Chen worked at Merck Research Laboratories, Janssen Pharmaceuticals of Johnson & Johnson, Mirati Therapeutics, and Bristol Myers Squibb before joining Asymchem. He has extensive experience designing, developing, and implementing robust, cost-effective, and green manufacturing routes for small molecule APIs, ensuring CMC compliance and quality, collaborating with cross-functional drug development teams and external partners, and supporting regulatory filings. Dr. Chen received his Ph.D. in organic chemistry from The Ohio State University.

About Asymchem

Asymchem is a comprehensive contract development and manufacturing organization (CDMO) with a complete continuum of support from preclinical to commercialization. Founded in 1997, Asymchem offers integrated solutions spanning the entire drug substance and drug product life cycle, backed by cutting-edge technology including flow chemistry and green manufacturing. With R&D and manufacturing operations in China, Europe, and the U.S. and a team of proven experts, we provide a full range of CDMO services for a global client base.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240626665787/en/

Jake Knorr
Senior Director of Marketing
Asymchem
Jakeknorr@asymchem.com

Logo

Images

Tags

More Like This

Advanced Manufacturing, Global Reach, and Streamlined Services — Asymchem Impresses at CPHI Milan 2024

Asymchem Secures Former Pfizer Sandwich, UK, Development and API Pilot Plant Manufacturing Facilities

Asymchem’s Fully Automated Peptide Production Lines Set New Benchmarks as Large-Scale Capacity Continues to Grow

Asymchem Welcomes Franck Mevellec as Senior Director, Business Development

Chemify Hires Biopharma Veteran Dr. Alastair Leighton as Chief Operating Officer

Medicilon Appoints Dr. Lilly Xu as Chief Technology Officer

Former Apple and Intel Executive Michael Bell Joins Chemify as Chief Technology Officer

Ex-FDA Expert Dr. Yaning Wang Joins Tsingke to Drive Small Nucleic Acid Drug Innovation